Abstract The global emergence of SARS-CoV-2 has triggered numerous efforts to develop therapeutic options for the COVID-19 pandemic. The main protease of SARS-CoV-2 ($M^{pro}$), a critical enzyme for the transcription and replication of the virus, is a key target for therapeutic development. While the organoselenium drug ebselen was recently demonstrated to have strong inhibition against $M^{pro}$ and potent antiviral activity, its molecular mode of action remained unknown, hindering further drug development. This study examines the binding modes of ebselen and its derivatives in $M^{pro}$ via high-resolution co-crystallography and investigates their chemical reactivity via mass spectrometry. Our findings reveal an unprecedented mechanism where a free selenium atom binds with Cysteine 145 of the $M^{pro}$ catalytic dyad, suggesting the hydrolysis of the enzyme-bound organoselenium covalent adduct. This "molecular hit-and-run" mechanism, confirmed by the identification of a phenolic byproduct via mass spectrometry, suggests wider therapeutic applications for organoselenium compounds against SARS-CoV-2 and other zoonotic beta-coronaviruses.
Introduction
To replicate effectively, SARS-CoV-2 relies on its main protease ($M^{pro}$) to cleave long viral polyproteins into functional units. Because humans do not possess a similar enzyme, $M^{pro}$ is a primary target for antiviral drug design. Ebselen, an existing drug with a known safety profile, was identified early in the pandemic as a potent $M^{pro}$ inhibitor. However, the lack of structural data regarding its exact "mode of action" prevented researchers from rationally designing more potent versions of the drug. This research addresses that gap by mapping the interaction between ebselen and the viral protease at the atomic level.
Methodology
The research team employed a multidisciplinary approach to observe the drug's interaction with the enzyme:
- High-Resolution Co-crystallography: The team grew crystals of the $M^{pro}$ enzyme bound with ebselen and its derivatives. Using high-energy X-rays at the Diamond Light Source, they mapped electron density at resolutions of 1.6–2.0 Å.
- Anomalous X-ray Scattering: To specifically locate the selenium atom within the enzyme's active site, the researchers used a specific X-ray wavelength near the selenium absorption edge.
- Mass Spectrometry (LC-MS/MS): Liquid chromatography-tandem mass spectrometry was utilized to identify the chemical byproducts released during the reaction, providing chemical evidence for the drug's transformation.
- Biological Assays: The team measured enzymatic inhibition ($IC_{50}$) and the ability of the compounds to rescue infected Vero E6 cells from viral replication ($EC_{50}$).
Results
An Unprecedented "Hit-and-Run" Mechanism
Most covalent inhibitors remain attached to their target. However, crystallographic studies of $M^{pro}$ with ebselen (PDB: 7BAK) and its derivative MR6-31-2 (PDB: 7BAL) revealed a unique mechanism. The drug acts as a delivery vehicle, donating a single selenium atom to the catalytic Cysteine-145 (Cys145) residue and then discarding the rest of the molecule. Crystallography showed 60–80% occupancy of a lone selenium atom in the active site, with no sign of the drug's original organic backbone.
The Role of Hydrolysis
The authors propose that after the initial binding, a conserved water molecule in the active site—assisted by the residue Histidine-41—triggers a hydrolysis reaction. This reaction breaks the drug apart, releasing a phenolic byproduct (salicylanilide) while leaving the selenium atom covalently bonded to the enzyme. Mass spectrometry confirmed this by showing the concentration of the byproduct increasing over time.
Potency and Antiviral Efficacy
The study evaluated five ebselen derivatives, several of which outperformed the parent compound:
- Enzymatic Inhibition: While ebselen showed an $IC_{50}$ of 670 nM, the derivative MR6-18-4 reached a more potent 345 nM.
- Cellular Rescue: In cell-based assays, MR6-31-2 demonstrated an $EC_{50}$ of 1.8 $\mu$M, significantly more effective than ebselen’s 4.67 $\mu$M at stopping viral replication in infected cells.
Discussion
The discovery of this "selenation" mechanism provides a new structural blueprint for developing high-potency organoselenium therapies. By understanding that ebselen functions by depositing a selenium atom, researchers can now focus on optimizing the delivery scaffold to improve the speed and specificity of this transfer.
While the study demonstrates high potency in vitro and in cell cultures, further research is required to determine the metabolic stability and pharmacokinetic properties of these derivatives in vivo. Additionally, it remains to be seen if this mechanism is unique to the SARS-CoV-2 $M^{pro}$ architecture or if it can be applied to other cysteine proteases. Nonetheless, the ebselen scaffold represents a promising starting point for a new class of antivirals effective against a broad range of zoonotic beta-coronaviruses.
Summary updated